Form 4: Mural Oncology Director Scott Thomas Jackson Granted Stock Options

Mural Oncology plc's Director, Scott Thomas Jackson, has been granted 8,637 stock options with an exercise price of $2.56, aligning his interests with the company's performance.

Summary

• Scott Thomas Jackson, a Director of Mural Oncology plc (MURA), was granted 8,637 stock options on June 11, 2025.
• Each option allows the purchase of one Ordinary Share at an exercise price of $2.56.
• The options will vest in full upon the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next Annual Meeting, contingent on Mr. Jackson's continued service with the Issuer.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Mr. Jackson directly beneficially owns 8,637 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's financial interests with the long-term success and share price performance of the company, fostering good corporate governance and incentivizing value creation.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The options have a long expiration date (June 10, 2035), providing ample time for potential value realization.

Risks

• The vesting of the options is subject to the reporting person's continued service with the Issuer, meaning the options could be forfeited if service ceases before vesting.
• The value of the options is dependent on the future market price of Mural Oncology plc's Ordinary Shares, which is subject to market volatility and company performance.

Future Outlook

The grant of stock options with a vesting schedule implies an expectation of continued service from Director Scott Thomas Jackson, aligning his future incentives with the company's long-term performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key personnel by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The practice of granting stock options to directors is a standard compensation mechanism widely adopted by public companies, including those in the oncology and biotechnology sectors, to align executive and director interests with shareholder value.
• Without specific details on the company's compensation philosophy, peer group comparisons, or the director's overall compensation package, a detailed assessment against industry benchmarks for the specific number of options (8,637) or exercise price ($2.56) is not feasible from this filing alone.

Corporate Governance

Related Party Transactions

• The grant of stock options to Scott Thomas Jackson, a Director of Mural Oncology plc, constitutes a related party transaction as it involves a transaction between the company and an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of director's interests with long-term share price appreciation.
• Employees: No direct impact mentioned, but such grants are part of a broader compensation framework that can affect morale and retention.

Next Steps

• The stock options will vest upon the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next Annual Meeting, subject to continued service.
• Upon vesting, Scott Thomas Jackson will have the right to exercise these options to acquire Ordinary Shares of Mural Oncology plc.

Key Dates

Keywords

Mural Oncology plc, MURA, Scott Thomas Jackson, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation, Beneficial Ownership